Clinical trials help researchers answer important medical questions, providing information that may help with the development of future treatment options. Clinical trials are conducted to determine if investigational treatments (such as new drugs, procedures, or medical devices) are safe and effective, so that the regulatory authority can decide whether they can be approved for use as a treatment.
Participation in a clinical trial is voluntary. You can withdraw at any time, for any reason (or no reason at all), and doing so will not affect the care you may be receiving now and may receive in the future.
Click here for the Learning about Clinical Trials brochure
Disclaimer: the videos and the brochure were produced by Biogen, a pharmaceutical company with whom we collaborate. This material does not intend to favor one or the other clinical trial, and CurePSP remains fully impartial in its support of clinical research.
Current Clinical Trials
For a current list of available clinical trials (sourced from the National Institutes of Health website, clinicaltrials.gov), please click on the following links:
Progressive Supranuclear Palsy
Corticobasal Degeneration
Multiple System Atrophy
CurePSP Genetics Program
The CurePSP Genetics Program is a nationwide initiative to increase our understanding of the genetic causes of PSP, CBS and MSA. The study will collect DNA from the comfort of your home and send the sample to the NIH for genetic testing. If a significant genetic variant is found, you have the option to receive the results from a genetic counselor. All activities are free of charge.
Learn More About the Genetics Program
TOPAZ Study
The goal of the TOPAZ study is to help people with Parkinson’s Disease and parkinsonism avoid fractures that can lead to loss of quality of life and physical function. The TOPAZ study will test if an FDA-approved medicine called zoledronate can prevent fractures and decrease the risk of death in those aged 60 and over, with Parkinson’s Disease or parkinsonism (including PSP and MSA), who have not had a hip fracture. TOPAZ is a home-based study and eligible participants can participate from their homes.
Learn more about this study here
AIDP Study
Opportunity to participate in a research trial! The University of Florida is looking for individuals with progressive supranuclear palsy (PSP), multiple system atrophy parkinsonian type (MSA-P) or Parkinson’s disease to participate in a study testing the performance of automated imaging differentiation of parkinsonism (AIDP) software in recognizing the different diagnoses. The study is being offered at over 20 locations across the U.S. and Canada.
Learn More Details On The Study, Eligibility, Locations And Contact Information
CYPRESS Trial
Have you been diagnosed with multiple system atrophy (MSA) and do you experience dizziness symptoms associated with neurogenic orthostatic hypotension (nOH)? If so, you may qualify. Symptomatic nOH affects approximately 70-90% of those with MSA, with symptoms such as dizziness, light-headedness, and feeling faint interfering with one's ability to perform daily activities- especially those requiring standing or walking.
The Phase 3 trial involves 9 visits over a 20-week study treatment period, followed by an optional 2-year long-term extension in which all participants receive the investigational drug. Participants may be eligible to participate in the study remotely (e.g., from your home) after an initial in-office study visit.
Please consider joining us in taking another critical step for patients with MSA toward the goal of nOH symptom relief.
Learn more about this study here
Treatment of Disturbed Sleep in PSP
UCSF is recruiting for a study to explore if specific sleep medications can improve your sleep patterns, disease symptoms, or quality of life. This is a 6-week remote clinical sleep trial in PSP, meaning you can fully participate from your own home with frequent phone calls with the study team.
ALLFTD
The ALL FTD study is recruiting people with PSP and CBD. The overall goal of ALLFTD is to prepare for future treatment trials by building a cohort of patients at expert centers who can be available for trials, collecting data on cognitive and behavioral assessments, imaging, blood and cerebral spinal fluid, and sharing data, images, and samples from participants with other researchers to further our knowledge of FTD. ALLFTD has two arms of the study: A Longitudinal Arm and a Biofluid Focused Arm. All visits include a participant and their study partner. Those in the Biofluid Arm will take part in the study during one of their clinical visits.
Learn more about this study here
PROSPER Trial
Ferrer is currently seeking individuals with PSP to participate in the PROSPER study, a clinical study phase II co-designed with patients and care partners to assess how safe and effective an investigational oral medicine called FNP-223 may be for treating PSP patients. After a screening assessment to confirm eligibility, participants will be randomly assigned to receive either the study medicine (FNP-223) or placebo. Participants will have a 50% chance of being randomly assigned to the group being given the study medicine (FNP-223). Both FNP-223 and placebo will be taken orally (as tablets) 3 times a day. Participation in the PROSPER Study includes 52 weeks of treatment period and involves a total of 7 visits in-person and 7 phone calls.
Learn more about this study here
Learn more about this study in spanish
ONO PHARMA USA
ONO PHARMA USA, the U.S. subsidiary of Ono Pharmaceutical Co., Ltd., is developing an investigational S1P5 receptor agonist, for multiple system atrophy (MSA), a rare, degenerative neurological disorder affecting your body's involuntary (autonomic) functions, including blood pressure, and motor control. There is no known cause for MSA, which affects potentially 15,000 to 50,000 Americans each year. ONO PHARMA USA is actively recruiting patients for a double-blind, parallel-group, placebo-controlled, Phase 2 clinical trial of an investigational S1P5 receptor agonist in patients with MSA in the U.S. For more information regarding this clinical trial, please email medinfo_us@ono-pharma.com or click the link below.
The FTD Disorders Registry
The Registry is an online database to collect information from those affected by all types of prime of life brain diseases, such as PSP, CBD, and related. Persons diagnosed, (current/former) caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures.